Non-every day statin administration — A literature review

Elis, Avishay; Lishner, Michael

doi:10.1016/j.ejim.2012.02.006

Cited by 15 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With 20 mg of lovastatin every other day, LDL-C levels were reduced by 21% and the drug was tolerated by 98% of the studied subjects. 40 A total of 5-10 mg of rosuvastatin twice weekly significantly decreased LDL-C levels by 26%, whereas changing doses of simvastatin from 10-20 mg daily to 40-80 mg twice weekly was not effective in reducing LDL-C levels. Weekly doses of 5-20 mg of rosuvastatin decreased LDL-C levels by 6-62% in a small series.…”

Section: Management Of Dyslipidaemiamentioning

confidence: 99%

“…4 Rosuvastatin every other day has been reported to lower LDL-C levels by 40.9% at a dose of 20 mg, by 39% at 10 mg and by 34% at a mean dose of 5.6 mg (range: 2.5-10 mg). 40,41 Additionally, atorvastatin every other day decreases LDL-C levels by 23% in comparison to 39% with daily dosing. With 20 mg of lovastatin every other day, LDL-C levels were reduced by 21% and the drug was tolerated by 98% of the studied subjects.…”

Section: Management Of Dyslipidaemiamentioning

confidence: 99%

“…Weekly doses of 5-20 mg of rosuvastatin decreased LDL-C levels by 6-62% in a small series. 40 Overall, non-daily regimens are better tolerated compared to daily dosing, but result in lower LDL-C reductions. 40 Nonetheless, even modest LDL-C reductions are thought to be useful in improving long-term outcomes; therefore, aiming for the highest tolerated dose is a reasonable endpoint.…”

Section: Management Of Dyslipidaemiamentioning

confidence: 99%

“…40 Overall, non-daily regimens are better tolerated compared to daily dosing, but result in lower LDL-C reductions. 40 Nonetheless, even modest LDL-C reductions are thought to be useful in improving long-term outcomes; therefore, aiming for the highest tolerated dose is a reasonable endpoint. 4 It is important to note, however, that while non-daily regimens are better tolerated, their use does not eliminate the possibility of on-going muscle pathology existing in the absence of clinical symptoms.…”

Section: Management Of Dyslipidaemiamentioning

confidence: 99%

“…Non-daily regimens include every other day, twice weekly and weekly dosing. 40 Rosuvastatin and atorvastatin have long half-lives which makes them suitable for non-daily dosing. 4 Rosuvastatin every other day has been reported to lower LDL-C levels by 40.9% at a dose of 20 mg, by 39% at 10 mg and by 34% at a mean dose of 5.6 mg (range: 2.5-10 mg).…”

Section: Management Of Dyslipidaemiamentioning

confidence: 99%

See 4 more Smart Citations

Statin-Associated Muscle Adverse Events: Update for clinicians

Al-Mohaissen¹,

Ignaszewski²,

Fröhlich³

et al. 2016

SQUMJ

View full text Add to dashboard Cite

Statins are potent medications which reduce low-density lipoprotein cholesterol (LDL-C) levels. Their efficacy in cardiovascular risk reduction is well established and indications for their use are expanding. While statins are generally well tolerated and safe, adverse events are relatively common, particularly statinassociated muscle adverse events (SaMAEs), which are the most frequently encountered type of adverse event. Recent guidelines and guideline updates on SaMAEs and statin intolerance have included revised definitions of SaMAEs, incorporating new evidence on their pathogenesis and management. As SaMAEs emerge as a therapeutic challenge, it is important for physicians to be aware of updates on management strategies to ensure better patient outcomes. The majority of patients who are considered statin-intolerant can nevertheless tolerate some forms of statin therapy and successfully achieve optimal LDL-C levels. This review article discusses the recent classification of SaMAEs with emphasis on pathogenesis and management strategies.

show abstract

Section: Management Of Dyslipidaemiamentioning

confidence: 99%